1. Home
  2. ZLAB vs AGIO Comparison

ZLAB vs AGIO Comparison

Compare ZLAB & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zai Lab Limited

ZLAB

Zai Lab Limited

HOLD

Current Price

$18.35

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$28.04

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZLAB
AGIO
Founded
2013
2007
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.0B
IPO Year
2017
2013

Fundamental Metrics

Financial Performance
Metric
ZLAB
AGIO
Price
$18.35
$28.04
Analyst Decision
Strong Buy
Buy
Analyst Count
5
8
Target Price
$49.60
$38.88
AVG Volume (30 Days)
598.6K
1.2M
Earning Date
05-07-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
38.46
N/A
EPS
N/A
N/A
Revenue
$460,156,000.00
$43,011,000.00
Revenue This Year
$9.75
$76.75
Revenue Next Year
$26.03
$170.73
P/E Ratio
N/A
N/A
Revenue Growth
15.33
N/A
52 Week Low
$15.96
$22.24
52 Week High
$44.34
$46.00

Technical Indicators

Market Signals
Indicator
ZLAB
AGIO
Relative Strength Index (RSI) 35.16 47.46
Support Level $16.88 $26.64
Resistance Level $19.64 $29.39
Average True Range (ATR) 0.95 1.15
MACD -0.51 0.03
Stochastic Oscillator 0.22 84.33

Price Performance

Historical Comparison
ZLAB
AGIO

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Share on Social Networks: